PetMed Express Stock Forecast, Price & News

-0.41 (-1.27 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $31.78
50-Day Range
MA: $33.97
52-Week Range
Now: $31.78
Volume267,956 shs
Average Volume789,151 shs
Market Capitalization$644.21 million
P/E Ratio21.19
Dividend Yield3.45%
PetMed Express, Inc., together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventative, flea and tick preventative, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies. It sells its products through its Internet website; telephone contact center; and direct mail/print through brochures and postcards. PetMed Express, Inc. was founded in 1996 and is headquartered in Delray Beach, Florida.
PetMed Express logo

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryInternet Retail
Current SymbolNASDAQ:PETS
Year FoundedN/A



Sales & Book Value

Annual Sales$284.13 million
Cash Flow$1.31 per share
Book Value$6.45 per share


Net Income$25.85 million


Market Cap$644.21 million
Next Earnings Date5/3/2021 (Estimated)


PetMed Express Is A Debt Free, Growth Bomb
April 12, 2021 |
PetMed Express (NASDAQ:PETS) Shares Down 4%
April 8, 2021 |
PetMed Express (NASDAQ:PETS) Stock Price Down 4.2%
April 1, 2021 |
PetMed Express Stock Is Believed To Be Fairly Valued
March 29, 2021 |
3 Top High-Yielding Stocks Trading 30% Off Their Highs
March 28, 2021 |
7 must-have products that make being a pet owner effortless
February 28, 2021 |
ROCE Insights For PetMed Express
February 9, 2021 |
See More Headlines


Overall MarketRank

1.75 out of 5 stars

Retail/Wholesale Sector

56th out of 383 stocks

Drug Stores & Proprietary Stores Industry

3rd out of 14 stocks

Analyst Opinion: 3.5Community Rank: 1.5Dividend Strength: 0.8Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
-0.41 (-1.27 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PETS News and Ratings via Email

Sign-up to receive the latest news and ratings for PETS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

PetMed Express (NASDAQ:PETS) Frequently Asked Questions

Is PetMed Express a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetMed Express in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PetMed Express stock.
View analyst ratings for PetMed Express
or view top-rated stocks.

What stocks does MarketBeat like better than PetMed Express?

Wall Street analysts have given PetMed Express a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PetMed Express wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PetMed Express' next earnings date?

PetMed Express is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for PetMed Express

How were PetMed Express' earnings last quarter?

PetMed Express, Inc. (NASDAQ:PETS) released its quarterly earnings results on Monday, January, 18th. The company reported $0.38 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.38. The company earned $65.90 million during the quarter, compared to analysts' expectations of $63.81 million. PetMed Express had a net margin of 9.82% and a trailing twelve-month return on equity of 22.79%. The company's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.34 EPS.
View PetMed Express' earnings history

How has PetMed Express' stock price been impacted by Coronavirus (COVID-19)?

PetMed Express' stock was trading at $25.95 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PETS shares have increased by 22.5% and is now trading at $31.78.
View which stocks have been most impacted by COVID-19

How often does PetMed Express pay dividends? What is the dividend yield for PetMed Express?

PetMed Express announced a quarterly dividend on Wednesday, January 20th. Stockholders of record on Monday, February 1st will be paid a dividend of $0.28 per share on Friday, February 12th. This represents a $1.12 annualized dividend and a dividend yield of 3.52%. The ex-dividend date is Friday, January 29th.
View PetMed Express' dividend history

Is PetMed Express a good dividend stock?

PetMed Express pays an annual dividend of $1.12 per share and currently has a dividend yield of 3.45%.
View PetMed Express' dividend history.

What price target have analysts set for PETS?

1 Wall Street analysts have issued 12-month price targets for PetMed Express' stock. Their forecasts range from $41.00 to $41.00. On average, they expect PetMed Express' stock price to reach $41.00 in the next year. This suggests a possible upside of 29.0% from the stock's current price.
View analysts' price targets for PetMed Express
or view top-rated stocks among Wall Street analysts.

Who are PetMed Express' key executives?

PetMed Express' management team includes the following people:
  • Mr. Menderes Akdag, CEO, Pres & Director (Age 60, Pay $664.26k)
  • Mr. Bruce S. Rosenbloom, CFO & Treasurer (Age 52, Pay $422.13k)
  • Wendy Zalai, Corp. Controller & Corp. Sec.

What is Mendo Akdag's approval rating as PetMed Express' CEO?

5 employees have rated PetMed Express CEO Mendo Akdag on Mendo Akdag has an approval rating of 46% among PetMed Express' employees. This puts Mendo Akdag in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of PetMed Express' key competitors?

What other stocks do shareholders of PetMed Express own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetMed Express investors own include Intel (INTC), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Verizon Communications (VZ), Netflix (NFLX) and Micron Technology (MU).

What is PetMed Express' stock symbol?

PetMed Express trades on the NASDAQ under the ticker symbol "PETS."

Who are PetMed Express' major shareholders?

PetMed Express' stock is owned by a variety of retail and institutional investors. Top institutional investors include Profit Investment Management LLC (0.49%), Rothschild Investment Corp IL (0.15%), State of Alaska Department of Revenue (0.07%), Crossmark Global Holdings Inc. (0.04%), Everence Capital Management Inc. (0.04%) and NEXT Financial Group Inc (0.02%). Company insiders that own PetMed Express stock include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag and Ronald J Korn.
View institutional ownership trends for PetMed Express

Which institutional investors are selling PetMed Express stock?

PETS stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL, and State of Alaska Department of Revenue. Company insiders that have sold PetMed Express company stock in the last year include Bruce S Rosenbloom, Gian Fulgoni, Menderes Akdag, and Ronald J Korn.
View insider buying and selling activity for PetMed Express
or view top insider-selling stocks.

Which institutional investors are buying PetMed Express stock?

PETS stock was purchased by a variety of institutional investors in the last quarter, including Everence Capital Management Inc., Profit Investment Management LLC, Crossmark Global Holdings Inc., and NEXT Financial Group Inc.
View insider buying and selling activity for PetMed Express
or or view top insider-buying stocks.

How do I buy shares of PetMed Express?

Shares of PETS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PetMed Express' stock price today?

One share of PETS stock can currently be purchased for approximately $31.78.

How much money does PetMed Express make?

PetMed Express has a market capitalization of $644.21 million and generates $284.13 million in revenue each year.

How many employees does PetMed Express have?

PetMed Express employs 214 workers across the globe.

What is PetMed Express' official website?

The official website for PetMed Express is

Where are PetMed Express' headquarters?

PetMed Express is headquartered at 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445.

How can I contact PetMed Express?

PetMed Express' mailing address is 420 SOUTH CONGRESS AVENUE, DELRAY BEACH FL, 33445. The company can be reached via phone at 561-526-4444.

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.